Flavocure Biotech Receives Orphan Drug Designation

Flavocure Biotech, LLC recently accomplished a major milestone — receiving Orphan Drug designation from the US Food and Drug Administration for their drug to treat acute myeloid leukemia.

Flavocure’s Founder and Executive Chairman, Dr. Henry Lowe, is a notable Jamaican scientist. Flavocure’s achievement is great news for Maryland and for Jamaica.

News of the US FDA approval was announced by the Prime Minister of Jamaica in a ceremony there last week. Several national news outlets covered the story, including The Gleaner and Jamaica Information Services.

Jamaica’s Primer Minister, Most Honorable Andrew Holness (right) congratulating Flavocure Founder and Executive Chairman Dr. Henry Lowe (left). Photo Credit: JIS Photographer

CEO of Flavocure, Ngeh Toyang, with the MD Department of Commerce at the BIO Int’l Convention in June. Photo Credit: MD Department of Commerce / Twitter

2 thoughts on “Flavocure Biotech Receives Orphan Drug Designation

Leave a Reply

Your email address will not be published. Required fields are marked *